Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Minocin
Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi Patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease.
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient.
Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial.
Accentia Biopharmaceuticals Announces that Revimmune Autoimmune Disease Therapy is Featured in Peer-review Journal
AMP-Activated Protein Kinase Restricts IFN-γ Signaling.
The safety of exercise training in multiple sclerosis: A systematic review.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis.
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis.
Reward responsiveness and fatigue in multiple sclerosis.
The value of the multiple sclerosis specialist nurse with respect to prevention of unnecessary emergency admission.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes.
Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis.
[The comparative study of efficacy and tolerability of intramuscular introduction of beta-interferon-1a in adults and adolescents with remitting multiple sclerosis.]
Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies.
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Gray matter is targeted in first-attack multiple sclerosis.
Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.

Pages